Business
Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.
About this update from Eisai Co., Ltd.
[{"type":"text","content":"Successfully started 216 patients on IBTROZI® (taletrectinib) in the fourth quarter of 2025, for a total of 432 new patient starts since launch in the second half of June 2025","length":175,"tagName":"p","attribs":{}},{"type":"text","content":"Entered into exclusive licensing and collaboration agreement with Eisai on January 11, 2026, for taletrectinib in Europe and additional countries outside U.S., China and Japan","length":175,"tagName":"p","attribs":{}},{"type":"text","content":"Published positive Phase 2 study results for safusidenib demonstrating durable responses for the treatment of grade 2 IDH1-mutant glioma","length":136,"tagName":"p","attribs":{}},{"type":"text","content":"Strong balance sheet with cash, cash equivalents, and marketable securities of $529.2 million as of December 31, 2025","length":117,"tagName":"p","attribs":{}},{"type":"text","content":"Company to host a conference call today at 4:30 pm ET","length":53,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, March 2, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.","length":297,"tagName":"p"},{"type":"image","alt":"Nuvation Bio logo (PRNewsfoto/Nuvation Bio, Inc.)","displaySize":"","headline":null,"caption":"Nuvation Bio logo (PRNewsfoto/Nuvation Bio, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":381,"height":153,"url":"https://media.zenfs.com/en/prnewswire.com/2fbe7ab68968d30cc6294fa8e90a5bfa"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oeKH5fU7G0DWOQ9CykKUng--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI4MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/2fbe7ab68968d30cc6294fa8e90a5bfa","width":381,"height":153}},"href":"https://mma.prnewswire.com/media/1017849/Nuvation_Bio_Inc_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""We ended our transformational 2025 with a strong fourth quarter that underscored IBTROZI's rapid adoption, and we believe our medicine is becoming the new standard of care for people living with advanced ROS1+ NSCLC across treatment lines. In 2026, we look forward to further building upon our successful U.S. launch, and ...